Design: Target trial emulation using National Joint Registry data (observational)
Population: 666,283 UK total hip replacements, 2018–2024 (10,203 robotic)
Primary outcome: Five-year implant survival, revision risk, and patient survival
Effect: Revision HR 0.96 (0.75–1.22); malposition revision HR 0.53 (0.30–0.93); implant survival 98.8% both

Using the National Joint Registry, a target-trial-emulation study compared 666,283 total hip replacements done between 2018 and 2024, of which 10,203 were robotic. Propensity-score matching created comparable groups to estimate the effect of the robotic approach.

Five-year implant survival was identical at 98.8% in both groups, with no difference in overall revision risk (hazard ratio 0.96, 95% CI 0.75–1.22) or intraoperative complications, and no difference in patient survival. Robotic surgery did lower the risk of revision for implant malposition — dislocation, leg-length discrepancy or malalignment (hazard ratio 0.53, 95% CI 0.30–0.93).

The honest reading is modest: a specific, uncommon failure mode is reduced, but overall implant and patient outcomes are no better, and robotic systems carry substantially higher capital and procedural costs. This is observational, so residual confounding cannot be excluded — relevant as robotic hip surgery is increasingly marketed in Indian private hospitals at a premium.

Robotic and conventional hip replacement had identical five-year implant survival at 98.8%.
Overall revision risk and intraoperative complications did not differ.
Robotic surgery lowered revision specifically for implant malposition (hazard ratio 0.53).
The gain is narrow and the costs are much higher, which matters where patients pay directly.

Why it matters

It challenges the premium charged for robotic hip surgery by showing the overall outcomes match conventional surgery.

The statistics, in plain English

A revision hazard ratio of 0.96 with an interval spanning 1.0 means no overall difference; the malposition figure of 0.53 clears 1.0, but as an observational subgroup it is a signal to weigh against cost, not proof.